Literature DB >> 32112342

Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer.

Gerasimos N Douridas1, Andreas Fountoulakis2, John Souglakos3, Sofia Gourtsoyianni4, Louiza Vini5, Georgia Levidou6, Theodoros Liakakos7, Christos Agalianos8, Christos Dervenis9, Maria Angeliki Kalogeridi10, Ioannis Karavokyros7, Anna Koumarianou11, Panteleimon Kountourakis12, Georgios Oikonomopoulos13, Panagiota Economopoulou11, Joseph Sgouros14, Spiros N Sgouros15, Konstantinos Stamou16, Charikleia Triantopoulou17, Dimitrios Zacharoulis18, Nikolaos Gouvas19, Evangelos Xynos20.   

Abstract

Gastric Cancer epidemics have changed over recent decades, declining in incidence, shifting from distal to proximal location, transforming from intestinal to diffuse histology. Novel chemotherapeutic agents combined with modern surgical operations hardly changed overall disease related survival. This may be attributed to a substantial inherent geographical variation of disease genetics, but also to a failure to standardize and implement treatment protocols in clinical practice. To overcome these drawbacks in Greece and Cyprus, a Gastric Cancer Study Group under the auspices of the Hellenic Society of Medical Oncology (HeSMO) and Gastrointestinal Cancer Study Group (GIC-SG) merged their efforts to produce a consensus considering ethnic parameters of healthcare system and the international proposals as well. Utilizing structured meetings of experts, a consensus was reached. To achieve further consensus, statements were subjected to the Delphi methodology by invited multidisciplinary national and international experts. Sentences were considered of high or low consensus if they were voted by ≥ 80%, or < 80%, respectively; those obtaining a low consensus level after both voting rounds were rejected. Forty-five statements were developed and voted by 71 experts. The median rate of abstention per statement was 9.9% (range: 0-53.5%). At the end of the process, one statement was rejected, another revised, and all the remaining achieved a high consensus. Forty-four recommendations covering all aspects of the management of gastric cancer and concise treatment algorithms are proposed by the Hellenic and Cypriot Gastric Cancer Study Group. The importance of centralization, care by a multidisciplinary team, adherence to guidelines, and individualization are emphasized.

Entities:  

Keywords:  Cyprus; Gastric cancer; Greece; Guidelines

Year:  2020        PMID: 32112342      PMCID: PMC7179795          DOI: 10.1007/s13304-020-00723-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  86 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  T Waddell; M Verheij; W Allum; D Cunningham; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

Review 3.  Treatment of early gastric cancer in the Western World.

Authors:  Elfriede Bollschweiler; Felix Berlth; Christoph Baltin; Stefan Mönig; Arnulf H Hölscher
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

4.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E C Smyth; M Verheij; W Allum; D Cunningham; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

5.  Endoscopic and histologic diagnosis of submucosal tumors of the gastrointestinal tract using combined strip biopsy and bite biopsy.

Authors:  M Karita; M Tada
Journal:  Gastrointest Endosc       Date:  1994 Nov-Dec       Impact factor: 9.427

6.  Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors.

Authors:  Irene Thomassen; Yvette R van Gestel; Bert van Ramshorst; Misha D Luyer; Koop Bosscha; Simon W Nienhuijs; Valery E Lemmens; Ignace H de Hingh
Journal:  Int J Cancer       Date:  2013-08-05       Impact factor: 7.396

7.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

Authors:  Ilfet Songun; Hein Putter; Elma Meershoek-Klein Kranenbarg; Mitsuru Sasako; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2010-04-19       Impact factor: 41.316

8.  Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT.

Authors:  J F Botet; C J Lightdale; A G Zauber; H Gerdes; S J Winawer; C Urmacher; M F Brennan
Journal:  Radiology       Date:  1991-11       Impact factor: 11.105

9.  A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.

Authors:  Edwin P M Jansen; Henk Boot; Mark P Saunders; Tom D L Crosby; Ria Dubbelman; Harry Bartelink; Marcel Verheij; Annemieke Cats
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-06       Impact factor: 7.038

Review 10.  Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?

Authors:  Rossella Reddavid; Silvia Sofia; Paolo Chiaro; Fabio Colli; Renza Trapani; Laura Esposito; Mario Solej; Maurizio Degiuli
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.